Red Clover
Natural health product licensed in Canada
- Licence holder
- Canadian Phytopharmaceuticals Corporation
- NPN or DIN-HM
- 80061440
- Status
- Active licence
- Licence date
- 2 June 2015
- Revision date
- 3 August 2016
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Trifolium pratense L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Trifolium pratense Source : Fleur Potency : 80 mg ÉAI Isoflavones | 200 milligramme | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Phosphate de calcium, dibasique, Dioxyde de silicium colloïdal, Cire de Carnauba, Hydroxypropylméthylcellulose, Carboxyméthylcellulose de sodium, Mélange de concentré de tocophérols, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | Not specified | 1 Comprimé | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps reduce severe and frequent hot flashes/flushes in post-menopausal women. Helps to reduce Bone Mineral Density losses with adequate intake of calcium and vitamin D in post-menopausal women. May support cardiovascular health. May reduce menopausal symptoms such as night sweats, sleeping disorders, nervousness, lack of concentration and vaginal dryness.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80061440
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2016. Photograph the packaging to check whether it has changed. Photograph the packaging